Switching from natalizumab to fingolimod-Reference-Cited by-同舟云学术

Switching from natalizumab to fingolimod

Published:2015-05-29 Issue:1 Volume:85 Page:29-39
ISSN:0028-3878
Container-title:Neurology
language:en
Short-container-title:Neurology

Author:

Kappos Ludwig,Radue Ernst-Wilhelm,Comi Giancarlo,Montalban Xavier,Butzkueven Helmut,Wiendl Heinz,Giovannoni Gavin,Hartung Hans-Peter,Derfuss Tobias,Naegelin Yvonne,Sprenger Till,Mueller-Lenke Nicole,Griffiths Sarah,von Rosenstiel Philipp,Gottschalk Rebecca,Zhang Ying,Dahlke Frank,Tomic Davorka

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical)

Reference22 articles.

1. Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

2. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

3. Switching From Natalizumab to Fingolimod in Multiple Sclerosis

4. Fingolimod after natalizumab and the risk of short-term relapse

5. Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals;Neurology and Therapy;2024-05-17

2. Personalized Use of Disease-Modifying Therapies in Multiple Sclerosis;Pharmaceutics;2024-01-17

3. Anxiety and Perception of Disease Control in Multiple Sclerosis Subjects Treated with Natalizumab;Journal of Clinical Medicine;2023-12-19

4. Multiple faces of multiple sclerosis in the era of highly efficient treatment modalities: Lymphopenia and switching treatment options challenges daily practice;International Immunopharmacology;2023-12

5. Real-world treatment outcomes and safety of natalizumab in Finnish multiple sclerosis patients;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2023-10